Jefferies reiterates Buy on Altimmune stock, keeps $28 target

Altimmune reported Q4 2025 EPS of -$0.27 vs -$0.25 forecast (an -8% surprise) and revenue of $26M vs $625M expected, a material miss. Shares trade at $3.09 near a 52-week low of $2.90; LTM free cash flow was negative $67.5M, though the company has more cash than debt and a strong current ratio of 18.55 after a recent capital raise. Jefferies reiterated Buy with a $28 PT and highlighted Phase 3 readiness for pemvidutide and strategic liver-franchise synergies; Truist initiated coverage with a Buy and H.C. Wainwright raised its PT to $25 while William Blair stayed Market Perform. The data imply significant execution and revenue risks near term despite bullish analyst theses on the drug franchise.

Analysis

The market is pricing this equity as a binary-funded development story, which creates pronounced optionality but also acute dilution and outcome risk. If the program demonstrates a real tolerability advantage versus crowded GLP-1-like entrants, second-order winners include specialty contract manufacturers and niche CROs with peptide experience — capacity constraints there can compress timelines and magnify value for early movers.

Near-term dynamics will be driven less by steady revenue growth and more by discrete regulatory alignments, financing tranches, and partnership signals across the next 6–18 months. Tail risks: a failed pivotal-like readout, a weak FDA interaction, or a large equity raise could wipe out implied upside quickly; catalysts that would reverse the trend are trial protocol amendments that materially raise success odds or a strategic collaboration that de-risks funding needs within 3–9 months.

From a market-structure standpoint, implied volatility on small biotech names makes outright longs expensive and slow to work; spreads and event structures extract optionality while capping premium decay. A pragmatic execution is to play asymmetric outcomes with defined-risk option spreads around key near-term milestones, paired with a sector hedge to neutralize broad risk-off flows that disproportionately hurt low-float names.

Consensus appears polarized: some analysts overweight future market share without fully accounting for commercialization execution risk and manufacturing scale; others over-penalize the name solely for recent quarterly miss without pricing in a partner or positive protocol tweaks. Position sizing should be event-driven, with maximum exposure limited to single-digit percentages of active risk and clear stop levels tied to financing events or regulatory newsflow.

Key Decisions for Investors

• ALT — Initiate a defined-risk LEAP call spread (buy long-dated call, sell higher strike) sized 1–2% of portfolio with a 9–18 month horizon; objective: 3x–5x payoff if pivotal/partnering news arrives; max loss = premium paid.
• ALT vs XBI — Pair trade: long the ALT call spread (as above) and short 0.5–1.0% notional of XBI to hedge sector derisking over 6–12 months; target asymmetric 2:1 reward-to-risk while neutralizing macro biotech weakness.
• ALT — If you prefer income/neutral view, sell a small put spread (cash-secured) for 3–6 months to collect premium and establish a lower-cost long if assigned; risk defined by the spread width, reward = premium collected.
• Risk management — Cut exposure to zero or hedge with additional long-dated puts if a large-capital raise is announced or if regulatory minutes indicate non-alignment; treat financing events as stop-loss triggers and re-assess on the next clear milestone.